AM-9022 is an orally active, potent, and selective inhibitor of KIF18A, a mitotic kinesin motor protein critical for chromosome alignment and segregation. It exhibits significant anti-cancer effects in human breast and ovarian tumor models.

AM-9022 is an orally active, potent, and selective inhibitor of KIF18A, a mitotic kinesin motor protein critical for chromosome alignment and segregation. It exhibits significant anti-cancer effects in human breast and ovarian tumor models.

Firmonertinib is an oral, brain-penetrant, mutant-selective inhibitor of EGFR. It targets a broad spectrum of EGFR mutations, including exon 20 insertions and the T790M resistance mutation. Firmonertinib is being developed as a first-line treatment for patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertions.

AM-9022 is an orally active, potent, and selective inhibitor of KIF18A, a mitotic kinesin motor protein critical for chromosome alignment and segregation. It exhibits significant anti-cancer effects in human breast and ovarian tumor models.

Firmonertinib is an oral, brain-penetrant, mutant-selective inhibitor of EGFR. It targets a broad spectrum of EGFR mutations, including exon 20 insertions and the T790M resistance mutation. Firmonertinib is being developed as a first-line treatment for patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertions.

Necrocide1 is a potent inducer of cancer cell necrosis and displays antiproliferative activity with IC50 values of 0.48 nM and 2 nM for MCF-7 and PC3 cells, respectively. Necrocide1 also exerts potent antitumor effects in xenograft models.

Firmonertinib is an oral, brain-penetrant, mutant-selective inhibitor of EGFR. It targets a broad spectrum of EGFR mutations, including exon 20 insertions and the T790M resistance mutation. Firmonertinib is being developed as a first-line treatment for patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertions.

Firmonertinib is an oral, brain-penetrant, mutant-selective inhibitor of EGFR. It targets a broad spectrum of EGFR mutations, including exon 20 insertions and the T790M resistance mutation. Firmonertinib is being developed as a first-line treatment for patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertions.

Necrocide1 is a potent inducer of cancer cell necrosis and displays antiproliferative activity with IC50 values of 0.48 nM and 2 nM for MCF-7 and PC3 cells, respectively. Necrocide1 also exerts potent antitumor effects in xenograft models.

Necrocide1 is a potent inducer of cancer cell necrosis and displays antiproliferative activity with IC50 values of 0.48 nM and 2 nM for MCF-7 and PC3 cells, respectively. Necrocide1 also exerts potent antitumor effects in xenograft models.